Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Paltusotine in Untreated Acromegaly
2021-001703-32Phase 3Active
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in acromegaly comparing Paltusotine with Placebo (2 arms). Primary endpoint: Biochemical response in IGF-1 at end of randomized control phase. Started Feb 2022; status: active.
02
Drugs
paltusotine
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2021-001703-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001703-32.